Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals

Basic and Clinical Pharmacology and Toxicology

Volumn 116, Issue 5, 2015, Pages 429-437

  Hoch, Matthias ^a   Darpo, Borje ^b,c   Brossard, Patrick ^a   Zhou, Meijian ^b   Stoltz, Randall ^d   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b ICardiac Technologies   (United States)

^c DANDERYD HOSPITAL   (Sweden)

^d D/b/a Covance GFI Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; MOXIFLOXACIN; PLACEBO; PONESIMOD; SPHINGOSINE 1 PHOSPHATE RECEPTOR; QUINOLONE DERIVATIVE; S1PR1 PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PROCEDURAL SITE REACTION; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SINGLE DRUG DOSE; SOMNOLENCE; THORAX PAIN; VISUAL IMPAIRMENT; ACTION POTENTIAL; ADOLESCENT; CHEMICALLY INDUCED; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; ELECTROCARDIOGRAPHY; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; LONG QT SYNDROME; METABOLISM; NORMAL HUMAN; PATHOPHYSIOLOGY; RISK ASSESSMENT; TIME; YOUNG ADULT;

ACTION POTENTIALS; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; FLUOROQUINOLONES; HEALTHY VOLUNTEERS; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; RECEPTORS, LYSOSPHINGOLIPID; RISK ASSESSMENT; THIAZOLES; TIME FACTORS; YOUNG ADULT;

EID: 84926378840     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12336     Document Type: Article

References (32)

1. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
3. Qureshi ZP, Seoane-Vazquez E, Rodriguez-Monguio R, Stevenson KB, Szeinbach SL. Market withdrawal of new molecular entities approved in the United States from 1980 to 2009. Pharmacoepidemiol Drug Saf 2011;20:772-7.
4. Fung M, Thornton A, Mybeck K, Wu JH-H, Hornbuckle K, Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Inf J 2001;35:293-317.
5. ICH Harmonized Tripartite Guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf (Last accessed on 16 Sep 2014).
6. ICH E14 Questions & Answers. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_QAs_R2_Step4.pdf. 2014 (Last accessed on 16 Sep 2014).
7. Bolli MH, Abele S, Binkert C, Bravo R, Buchmann S, Bur D et al. 2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists. J Med Chem 2010;53:4198-211.
8. Piali L, Froidevaux S, Hess P, Nayler O, Bolli MH, Schlosser E et al. The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 2011;337:547-56.
9. Aarthi JJ, Darendeliler MA, Pushparaj PN. Dissecting the role of the S1P/S1PR axis in health and disease. J Dent Res 2011;90:841-54.
10. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 2012;22:50-60.
11. Horga A, Castilló J, Montalban X. Fingolimod for relapsing multiple sclerosis: an update. Expert Opin Pharmacother 2010;11:1183-96.
12. Thangada S, Khanna KM, Blaho VA, Oo ML, Im DS, Guo C et al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med 2010;207:1475-83.
13. Olsson T, Boster A, Fernández O, Freedman MS, Pozzilli C, Bach D et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry 2014;85:1198-208, doi: 10.1136/jnnp/2013/307282.
14. Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol 2013;76:888-96.
15. 1 receptor modulator: favorable impact of dose up-titration. J Clin Pharmacol 2014. doi:10.1002/jcph.244.
16. 1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects. Eur J Pharm Sci 2014;63C:147-53.
17. Schmouder R, Serra D, Wang Y, Kovarik JM, Dimarco J, Hunt TL et al. FTY720: Placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol 2006;46:895-904.
18. Reyes M, Hoch M, Brossard P, Wagner-Redeker W, Miraval T, Dingemanse J. Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans. Xenobiotica 2014;4:1-11.
19. Darpo B. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 2010;159:49-57.
20. Darpo B, Fossa AA, Couderc JP, Zhou M, Schreyer A, Ticktin M et al. Improving the precision of QT measurements. Cardiol J 2011;18:401-10.
21. Gibaldi M, Perrier D. Pharmacokinetics. Dekker, New York, NY, 1982.
22. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
23. Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol 2008;48:13-8.
24. Florian J, Tornøe CW, Brundage R, Parekh A, Garnett CE. Population pharmacokinetic and concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol 2011;51:1152-62.
25. Vaclavkova A, Chimenti S, Arenberger P, Holló P, Sator P-G, Burcklen M et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014; doi:10.1016/S0140-6736(14)60803-5.
26. Malik M, Garnett CE, Zhang J. Thorough QT studies: questions and quandaries. Drug Saf 2010;33:1-14.
27. Dixon R, Job S, Oliver R, Tompson D, Wright JG, Maltby K et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol 2008;66:396-404.
28. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther 2008;84:475-80.
29. Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12:756-67.
30. Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov 2013;12:688-702.
31. ® prescribing information. Novartis Pharmaceuticals Corporation, April 2014.
32. Fingolimod. Clinical pharmacology/biopharmaceutics review. FDA: www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022527Orig1s000clinpharmr.pdf (last accessed on 16 Sep 2014).